ARCH-backed HI-Bio touts ear­ly da­ta from two tri­als for rare kid­ney dis­ease

A kid­ney-spe­cif­ic au­toim­mune dis­ease with no ap­proved ther­a­pies could face an op­po­nent in felzartam­ab, an in­ves­ti­ga­tion­al mon­o­clon­al an­ti­body, ac­cord­ing to its de­vel­op­er.

Da­ta from two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER